A year af­ter with­draw­ing IPO, Dy­nacure scraps lead drug for rare mus­cle dis­eases

The French biotech Dy­nacure is scrap­ping its lead drug af­ter run­ning in­to trou­ble dur­ing an ear­ly-stage study.

While at­tempt­ing to move from the low-dose co­hort …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER